Seeking Alpha

Recent Phase III study results published in the New England Journal of Medicine show Novartis'...

Recent Phase III study results published in the New England Journal of Medicine show Novartis' (NVS) drug canakinumab significantly relieves symptoms in patients with a serious form of childhood arthritis. The drug was assessed in two trials and both showed canakinumab provided substantial symptom relief and delayed disease flare recurrence, thus allowing patients to substantially reduce or discontinue use of corticosteroids.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|